<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595994</url>
  </required_header>
  <id_info>
    <org_study_id>GEIS-67</org_study_id>
    <nct_id>NCT04595994</nct_id>
  </id_info>
  <brief_title>Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma</brief_title>
  <official_title>Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I-II, randomized, open-label, multicenter, international clinical trial Patients with&#xD;
      advanced soft-tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, alveolar&#xD;
      soft-part sarcoma) and osteosarcoma will receive selinexor in combination with gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I-II, randomized, open-label, multicenter, international clinical trial Patients with&#xD;
      advanced soft-tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, alveolar&#xD;
      soft-part sarcoma) and osteosarcoma will receive selinexor in combination with gemcitabine.&#xD;
&#xD;
      In the Phase I part safety and toxicity of the combination will be assessed using a 3+3&#xD;
      design. The recommended dose for the Phase II will be determined.&#xD;
&#xD;
      In the Phase II part there will be 4 different cohorts:&#xD;
&#xD;
      Cohort 1: Undifferentiated pleomorphic sarcoma (UPS) Cohort 2: Leiomyosarcoma (LMS) Cohort 3:&#xD;
      Alveolar soft-part sarcoma (ASPS) Cohort 4: Osteosarcoma Patients will be randomized for&#xD;
      phase II part only (except in cohort 3) in an open-label way to receive selinexor in&#xD;
      combination with gemcitabine versus gemcitabine alone&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>unique arms for each possible dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the maximum tolerated dose (MTD) or the recommended dose for phase II of Selinexor plus gemcitabine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile according to CTCAE 5.0.</measure>
    <time_frame>6 months</time_frame>
    <description>Safety profile of the experimental treatment, through assessment of adverse event type, incidence, severity, time of appearance, related causes, as well as physical explorations and laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR).</measure>
    <time_frame>6 months</time_frame>
    <description>Objective Response Rate (ORR): ORR is defined as the number of subjects with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) divided by the number of response evaluable subjects (according to RECIST 1.1 criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate efficacy according to Choi response</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy measured through tumor response according to Choi criteria. The evaluation criteria will be based on the identification of target lesions in baseline and their follow-up until tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients's quality of life (QoL)</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life will be measured with European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic values in blood analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Impact of pharmacokinetics. interactions between selinexor in gemcitabine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Sarcoma,Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Selinexor + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation levels (Phase I):&#xD;
All included patients will take both drugs:&#xD;
Selinexor weekly (given on days 1,8 and 15 of each cycle) will be dispensed at different dose levels: dose level 1:60 mg, dose level 2: 60 mg, dose level 3: 60 mg, and dose level 4: 80 mg).&#xD;
Gemcitabine weekly (given on days 1, 8 of each cycle) will be administered at different dose levels: (dose level 1:1000 mg/m2 (30 min), dose level 2:1000 mg/m2 (10 mg/m2/min), dose level 3:1200 mg/m2 (10 mg/m2/min) and dose level 4: 1200 mg/m2 (10 mg/m2/min)).&#xD;
Selinexor: tablet (20 mg tablets) Oral use.&#xD;
Gemcitabine: Concentrate for solution for infusion. Intravenous use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).</description>
    <arm_group_label>Selinexor + Gemcitabine</arm_group_label>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must provide written informed consent prior to performance of any&#xD;
             study-specific procedures and must be willing to comply with treatment and follow-up.&#xD;
             Informed consent must be obtained prior to start of the screening process. Procedures&#xD;
             conducted as part of the patient's routine clinical management (e.g. imaging tests),&#xD;
             obtained prior to signature of informed consent may be used for screening or baseline&#xD;
             purposes as long as these procedures are conducted as specified in the protocol.&#xD;
&#xD;
          2. Age: 18-80 years&#xD;
&#xD;
          3. Histologic diagnosis of soft tissue sarcoma (undifferentiated pleomorphic sarcoma,&#xD;
             leiomyosarcoma, alveolar soft part sarcoma) or osteosarcoma confirmed by central&#xD;
             pathology review prior to enrolment with an archive tumor sample. A fresh paraffin&#xD;
             embedded tumor tissue block must be provided for all subjects for biomarker analysis&#xD;
             before and (when feasible) after treatment with investigational products.&#xD;
&#xD;
          4. Metastatic/advanced disease in progression in the last 6 months.&#xD;
&#xD;
          5. Patients have previously received at least one previous line of systemic therapy&#xD;
&#xD;
          6. Measurable disease according to RECIST 1.1 criteria.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          8. Adequate hepatic, renal, cardiac, and hematologic function.&#xD;
&#xD;
          9. Laboratory tests as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
         10. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan.&#xD;
&#xD;
         11. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 72 hours prior to enrollment and agree to use birth control measures during&#xD;
             study treatment and for 3 months after its completion. Patients must not be pregnant&#xD;
             or nursing at study entry. Women/men of reproductive potential must have agreed to use&#xD;
             an effective contraceptive method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Three or more previous lines of chemotherapy&#xD;
&#xD;
          2. Prior selinexor or another XPO1 inhibitor treatment.&#xD;
&#xD;
          3. Administration of a previous gemcitabine-containing treatment.&#xD;
&#xD;
          4. Any concurrent medical condition or disease (e.g. uncontrolled active hypertension,&#xD;
             uncontrolled active diabetes, active systemic infection, etc.) that is likely to&#xD;
             interfere with study procedures.&#xD;
&#xD;
          5. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic&#xD;
             antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.&#xD;
&#xD;
          6. Pregnant or breastfeeding females.&#xD;
&#xD;
          7. Body surface area (BSA) &lt;1.4 m2 at baseline, calculated by the Du Bois(31) or&#xD;
             osteller(32) method.&#xD;
&#xD;
          8. Life expectancy of less than 3 months.&#xD;
&#xD;
          9. Major surgery within 4 weeks prior to C1D1.&#xD;
&#xD;
         10. Any active gastrointestinal dysfunction interfering with the patient's ability to&#xD;
             swallow tablets, or dysfunction that could interfere with absorption of study&#xD;
             treatment.&#xD;
&#xD;
         11. Inability or unwillingness to take supportive medications such as anti-nausea and&#xD;
             anti-anorexia agents as recommended by the NCCN CPGO for antiemesis and&#xD;
             anorexia/cachexia (palliative care).&#xD;
&#xD;
         12. Any active, serious psychiatric, medical, or other conditions/situations that, in the&#xD;
             opinion of the Investigator, could interfere with treatment, compliance, or the&#xD;
             ability to give informed consent.&#xD;
&#xD;
         13. Presence of brain or central nervous system metastases, unless they are controlled&#xD;
             (patients with treated and stable metastasis are eligible).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Martín Broto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiomar Rodriguez Beloso</last_name>
    <phone>+34 971 439 900</phone>
    <email>grodriguez@sofpromed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margalida Frau</last_name>
    <phone>+34 971 439 900</phone>
    <email>mfrau@sofpromed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>HU Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martín Broto, MD</last_name>
      <email>jmartin@atbsarc.org</email>
    </contact>
    <investigator>
      <last_name>Javier Martín Broto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Casado, MD</last_name>
      <email>antoniocasado6@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo, MD</last_name>
      <email>aredondo12@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martínez Trufero, MD</last_name>
    </contact>
    <contact_backup>
      <email>jmtrufero@seom.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kashyap T, Argueta C, Unger T, Klebanov B, Debler S, Senapedis W, Crochiere ML, Lee MS, Kauffman M, Shacham S, Landesman Y. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. Oncotarget. 2018 Jul 20;9(56):30773-30786. doi: 10.18632/oncotarget.25637. eCollection 2018 Jul 20.</citation>
    <PMID>30112106</PMID>
  </reference>
  <reference>
    <citation>Park KS, Han BG, Lee KH, Kim DS, Kim JM, Jeon H, Kim HS, Suh SW, Lee EH, Kim SY, Lee BI. Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells. Cancer Lett. 2009 Feb 18;274(2):201-7. doi: 10.1016/j.canlet.2008.09.007. Epub 2008 Oct 11.</citation>
    <PMID>18851895</PMID>
  </reference>
  <reference>
    <citation>Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis. 2013 Sep 5;4:e791. doi: 10.1038/cddis.2013.307.</citation>
    <PMID>24008735</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

